These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Regulation of insulin-like growth factor binding protein-1 during the 24-hour metabolic clock and in response to hypoinsulinemia induced by fasting and Sandostatin in normal women. Holden JP; Butzow TL; Laughlin GA; Ho M; Morales AJ; Yen SC J Soc Gynecol Investig; 1995; 2(1):38-44. PubMed ID: 9420847 [TBL] [Abstract][Full Text] [Related]
11. Altered regulation of insulin-like growth factor binding protein-1 in patients with polycystic ovary syndrome. Carmina E; Stanczyk FZ; Morris RS; Lee PD; Savjani G; Lobo RA J Soc Gynecol Investig; 1995; 2(6):743-7. PubMed ID: 9420884 [TBL] [Abstract][Full Text] [Related]
12. The effect of epidermal growth factor on circulating levels of free and total IGF-I and IGF-binding proteins in adult rats. Frystyk J; Vinter-Jensen L; Skjaerbaek C; Flyvbjerg A Growth Regul; 1996 Mar; 6(1):48-54. PubMed ID: 8717450 [TBL] [Abstract][Full Text] [Related]
13. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly. Quabbe HJ; Plöckinger U J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912 [TBL] [Abstract][Full Text] [Related]
14. Octreotide: a long-acting inhibitor of endogenous hormone secretion for human metabolic investigations. Krentz AJ; Boyle PJ; Macdonald LM; Schade DS Metabolism; 1994 Jan; 43(1):24-31. PubMed ID: 8289671 [TBL] [Abstract][Full Text] [Related]
15. Short stature associated with high circulating insulin-like growth factor (IGF)-binding protein-1 and low circulating IGF-II: effect of growth hormone therapy. Barreca A; Bozzola M; Cesarone A; Steenbergh PH; Holthuizen PE; Severi F; Giordano G; Minuto F J Clin Endocrinol Metab; 1998 Oct; 83(10):3534-41. PubMed ID: 9768660 [TBL] [Abstract][Full Text] [Related]
16. The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients. van der Hoek J; van der Lelij AJ; Feelders RA; de Herder WW; Uitterlinden P; Poon KW; Boerlin V; Lewis I; Krahnke T; Hofland LJ; Lamberts SW Clin Endocrinol (Oxf); 2005 Aug; 63(2):176-84. PubMed ID: 16060911 [TBL] [Abstract][Full Text] [Related]
17. Effects of repeated doses and continuous infusions of the growth hormone-releasing peptide hexarelin in conscious male rats. Conley LK; Gaillard RC; Giustina A; Brogan RS; Wehrenberg WB J Endocrinol; 1998 Sep; 158(3):367-75. PubMed ID: 9846166 [TBL] [Abstract][Full Text] [Related]
18. Lack of growth hormone effect on insulin-associated suppression of insulinlike growth factor binding protein 1 in humans. Conover CA; Butler PC; Wang M; Rizza RA; Lee PD Diabetes; 1990 Oct; 39(10):1251-6. PubMed ID: 1698676 [TBL] [Abstract][Full Text] [Related]